Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Operating Leases: 2019-2024

Historic Operating Leases for Tg Therapeutics (TGTX) over the last 6 years, with Dec 2024 value amounting to $8.1 million.

  • Tg Therapeutics' Operating Leases fell 13.20% to $7.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.3 million, marking a year-over-year decrease of 13.20%. This contributed to the annual value of $8.1 million for FY2024, which is 11.89% down from last year.
  • Latest data reveals that Tg Therapeutics reported Operating Leases of $8.1 million as of FY2024, which was down 11.89% from $9.2 million recorded in FY2023.
  • In the past 5 years, Tg Therapeutics' Operating Leases registered a high of $10.4 million during FY2020, and its lowest value of $8.1 million during FY2024.
  • In the last 3 years, Tg Therapeutics' Operating Leases had a median value of $9.2 million in 2023 and averaged $9.2 million.
  • Per our database at Business Quant, Tg Therapeutics' Operating Leases climbed by 5.05% in 2022 and then decreased by 11.89% in 2024.
  • Over the past 5 years, Tg Therapeutics' Operating Leases (Yearly) stood at $10.4 million in 2020, then declined by 5.43% to $9.8 million in 2021, then grew by 5.05% to $10.3 million in 2022, then declined by 10.76% to $9.2 million in 2023, then fell by 11.89% to $8.1 million in 2024.